GammaTile

Introducing
tile-based
radiation therapy

GammaTile® is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms.

Bioresorbable, conformable collagen tile

How it works

  • Tiles are placed into the operative bed, covering the oncologically at-risk surfaces of the tumor cavity.1,2
  • Tiles conform to the cavity and the hydrophilic collagen keeps it in place.1,2
  • The number of tiles used is customized to each patient and determined by the size and location of tumor.1,2
  • Implanted directly into the tumor cavity at the time of resection, GammaTile immediately starts delivering a targeted therapeutic dose to possible remaining tumor cells.1,2
  • The collagen tile keeps the radiation source away from healthy tissue, reducing the risk of radiation side effects.1-10
  • Favorable depth-dose profile optimizes local tumor control.1-10
  • Uniform radiation-source spacing helps give a predictable, therapeutic radiation dose.1

Achieve local control
with optimized dosimetry.

50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.11

88% of the dose is delivered in ~30 days.10

Overtime, after the therapeutic dose has been delivered, the collagen is naturally resorbed by the body.2

The GammaTile Commitment Pledge
for recurrent brain tumors

If a GammaTile treatment of a recurrent brain tumor is canceled because intraoperative pathology reveals only necrotic tissue, we will update the invoice to reflect a $0 charge.*

CONTACT USORDER NOW
* Per the GammaTile Commitment Product Policy, effective December 31, 2023. A purchase order must be submitted for the original order and the customer must not have any past due invoices with GT Medical Technologies. Additional Terms and Conditions apply. Please contact Customer Service for complete policy details.

REFERENCE: 1. Garcia MA, et al. J Neurooncol. 166:203-212 (2024). 2. Gessler DJ, et al. Future Oncol. 16(30):2445-2455 (2020). 3. Dharnipragada R, et al. Neurooncol Adv. 5(1):vdad062 (2023). 4. Nakaji P, et al. Cureus. 12(11):e11570 (2020). 5. Imber BS, et al. J Neurooncol. 159(3):609-618 (2022). 6. Kutuk T, et al. Brachytherapy. 22(6):872-881 (2023). 7. Gessler DJ, et al. Neurooncol Adv. 4(1):1-11 (2022). 8. Smith N, et al. Neuro Oncol. 24(S6):S4-S15 (2022). 9. Yekula A, et al. J Neurooncol. 166(3):441-450 (2024). 10. Brachman DG, et al. J Neurosurg. 131(6):1819-1828 (2018). 11. Ekhator C, et al. Cureus. 14(1):e29970 (2022).
MKT-478-01